Altium Capital
Crossover fundNew York · Seed–Growth · 5 people tracked
Investment thesis
Altium Capital Management provides growth capital to private and public healthcare companies developing novel technologies for human health. Its investment universe centers on therapeutics within private ventures, small-cap and micro-cap public companies, seeking firms with transformative catalysts ahead, many raising institutional capital for the first time. The firm supports early-stage ventures in pre-clinical development phases, aiming for long-term partnerships and participation across multiple financing rounds. Altium also helps companies attract additional capital through its network of like-minded investors, relying on rigorous research and due diligence to invest with a long-term horizon in promising new technologies.
Source: firm website, verified Aug 7, 2026.
Team · 5 people
from the firm's website
What they invest in
from 11 of 17 portfolio companiesBiotech ×10Healthtech ×6Deep Tech ×2Medical Devices ×2AI & Machine Learning ×1Digital Health ×1
HQs:United States×4
Investments · 17 tracked
founders shown can be your intro pathHyperfine makes the Swoop system, an AI-powered portable brain MRI that uses an ultra-low-field (0.064T) magnet to bring imaging to the point of care in hospitals, neurology clinics, and pediatric settings.
AI & Machine LearningHealthtechMedical Devices
Co-investorsColle Capital PartnersDolby Family Ventures
Opus Genetics (formerly Ocuphire) is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies and other treatments for inherited retinal diseases (IRDs) and other retinal and refractive disorders.
BiotechDeep TechDigital Health
Co-investorsCapital Midwest FundID Ventures
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)Tamra Adams(Executive Officer)Abel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAvego BioScience CapitalPontifax Venture Capital
eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
BiotechDeep TechMedical Devices
Mike Curtis, Ph.D.(President & Chief Executive Officer)
Co-investorsAlta PartnersEisai Innovation, Inc.Fresenius Medical Care VenturesKhosla VenturesLux Capital
Hummingbird Bioscience develops antibody-based therapeutics, including antibody-drug conjugates (ADCs), using proprietary linker-payload and biologics discovery platforms.
BiotechHealthtech
Co-investorsClavystBioDecheng CapitalDroia VenturesFrazier Life SciencesKiwoom InvestmentMuirwoods Ventures+1 more
Immunovant is a clinical-stage biopharmaceutical company developing treatments for people with autoimmune diseases, with a focus on therapies targeting the FcRn receptor.
BiotechHealthtechNew York, US
Christopher Van Tuyl(Executive Officer)Michael Geffner(Executive Officer)Pete Salzmann(Executive Officer, Director)Jay Stout(Executive Officer)Melanie Gloria(Executive Officer)Eva Renee Barnett(Executive Officer)
Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases, including its lead candidate PALI-2108, based on a PDE4 prodrug platform.
Biotech
Quoin Pharmaceuticals is a pharmaceutical company developing therapeutic products for rare diseases, with a lead candidate, QRX003, in clinical trials for Netherton Syndrome.
BiotechHealthtechAshburn, US
Michael Myers(Executive Officer, Director)Denise Carter(Executive Officer, Director)MICHAEL MEYERS(Executive Officer, Director)Sally Bridget Lawlor(Executive Officer)Eyal Leibovitz(Executive Officer)Shai Yarkoni(Executive Officer, Director)
Sagimet is a clinical-stage biopharmaceutical company developing FASN (fatty acid synthase) inhibitors targeting metabolic and fibrotic disease pathways driven by overproduction of the fatty acid palmitate.
BiotechHealthtech
Co-investorsHM Venture Partners
BiotechNew York, US
Raj Mehra(Chief Executive Officer)Michael Golembiewski(Chief Financial Officer)BRIAN DORSEY(Executive Officer)CATHERINE BOVENIZER(Executive Officer)NEIL MORTON(Executive Officer)
BoardBrian Lian(Director)
Co-investorsSanofi VenturesDolby Family Ventures
Exits · 1
IPOs and acquisitions across the tracked portfolioHyperfineNASDAQ: HYPR
Portfolio news
latest coverage across their companiesChemomab · stocktitan.net · Aug 13, 2026
Frequently asked questions
- How many investments has Altium Capital made?
- Altium Capital has 17 tracked investments, including 1 dated in the last 24 months.
- What stage does Altium Capital invest at?
- Altium Capital invests at the Seed, Series A, Growth stages.
- What sectors does Altium Capital focus on?
- Altium Capital focuses on Biotech, Crypto & Web3, Digital Health, Healthtech, Medical Devices.
- Where is Altium Capital located?
- Altium Capital is headquartered in New York, US.
- Who does Altium Capital co-invest with?
- Altium Capital most often shares deals with Aisling Capital, Khosla Ventures, Lux Capital, among 21 tracked co-investors.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
F-Prime Capital Partners is a venture capital firm whose team of scientists, engineers, physicians, operators, and investors supports companies in scaling and accelerating growth.
NJF Capital is the venture investment arm of NJF Holdings, the private investment group founded by Nicole Junkermann. It backs transformative entrepreneurs building industry-defining technologies with global scale potential.